Abstract
Background
Cardiac safety of new drugs is essential for public health. Nav1.5 is the cardiac sodium channel responsible for action potentials in cardiomyocytes.
Objective
For high-throughput cardiotoxicity assays in the development of antiarrhythmic drugs, we have established an electrophysiologically validated stable HEK293 cell line expressing human Nav1.5 (hNav1.5). To validate the cell line, we examined the effects of lidocaine, an antiarrhythmic agent, and compared its effects using conventional and automated patch-clamp systems.
Results
We isolated three stable cell lines originating from a single clonal cell and selected one stable cell line that produced a minimum 5 nA of hNav1.5 currents without any change in biophysical properties compared to the current from the transiently expressed hNav1.5. We further compared the pharmacological effects of lidocaine on this cell line using the conventional patch-clamp and automated patch-clamp systems. Lidocaine blocked hNav1.5 currents in a concentration- and voltage-dependent manner. The IC50 values at holding potentials of − 90 mV, near the resting membrane potential of cardiomyocytes, and − 120 mV were 18.4 ± 2.6 μM and 775.6 ± 37.1 μM, respectively. In the automated patch-clamp system, the IC50 values at holding potentials of − 90 mV and − 120 mV were 17.9 ± 2.0 μM and 578.7 ± 74.3 μM, respectively, indicating no difference between the systems. In both systems, lidocaine caused significant shifts toward hyperpolarization in the steady-state inactivation curves by ~ 20 mV and induced slower recovery from inactivation and stronger use-dependent inhibition.
Conclusion
The new HEK293 cell line stably expressing hNav1.5 channels produced a current that could be tested using both conventional and automated patch-clamp systems with similar results. This current would be strong enough to evaluate cardiac safety, thus allowing the use of the automated patch-clamp system for drug screening and functional kinetic studies to reveal the mechanism of drug action.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Abriel H (2010) Cardiac sodium channel Na(v)1.5 and interacting proteins: physiology and pathophysiology. J Mol Cell Cardiol 48(1):2–11. https://doi.org/10.1016/j.yjmcc.2009.08.025
Barchi RL (1988) Probing the molecular structure of the voltage-dependent sodium channel. Annu Rev Neurosci 11:455–495. https://doi.org/10.1146/annurev.ne.11.030188.002323
Bean BP, Cohen CJ, Tsien RW (1983) Lidocaine block of cardiac sodium channels. J Gen Physiol 81(5):613–642
Courtney KR (1975) Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther 195(2):225–236
Hanck DA, Nikitina E, McNulty MM, Fozzard HA, Lipkind GM, Sheets MF (2009) Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. Circ Res 105(5):492–499. https://doi.org/10.1161/CIRCRESAHA.109.198572
Hill RJ, Duff HJ, Sheldon RS (1989) Class I antiarrhythmic drug receptor: biochemical evidence for state-dependent interaction with quinidine and lidocaine. Mol Pharmacol 36(1):150–159
Hille B (2001) Ion channels of excitable membranes, 3rd edn. Sinauer, Sunderland, MA
Liu H, Atkins J, Kass RS (2003) Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol 121(3):199–214
Maltsev VA, Undrovinas AI (2006) A multi-modal composition of the late Na+ current in human ventricular cardiomyocytes. Cardiovasc Res 69(1):116–127
McNulty MM, Edgerton GB, Shah RD, Hanck DA, Fozzard HA, Lipkind GM (2007) Charge at the lidocaine binding site residue Phe-1759 affects permeation in human cardiac voltage-gated sodium channels. J Physiol 581(Pt 2):741–755. https://doi.org/10.1113/jphysiol.2007.130161
Neher E, Sakmann B (1976) Single-channel currents recorded from membrane of denervated frog muscle fibres. Nature 260(5554):799–802
Nerbonne JM, Kass RS (2005) Molecular physiology of cardiac repolarization. Physiol Rev 85(4):1205–1253. https://doi.org/10.1152/physrev.00002.2005
Rogart RB, Cribbs LL, Muglia LK, Kephart DD, Kaiser MW (1989) Molecular cloning of a putative tetrodotoxin-resistant rat heart Na+ channel isoform. Proc Natl Acad Sci USA 86(20):8170–8174
Song W, Xiao Y, Chen H, Ashpole NM, Piekarz AD, Ma P, Hudmon A, Cummins TR, Shou W (2012) The human Nav1.5 F1486 deletion associated with long QT syndrome leads to impaired sodium channel inactivation and reduced lidocaine sensitivity. J Physiol 590(20):5123–5139. https://doi.org/10.1113/jphysiol.2012.235374.
Stadnicka A, Kwok WM, Hartmann HA, Bosnjak ZJ (1999) Effects of halothane and isoflurane on fast and slow inactivation of human heart hH1a sodium channels. Anesthesiology 90(6):1671–1683
Strichartz GR (1973) The inhibition of sodium currents in myelinated nerve by quaternary derivatives of lidocaine. J Gen Physiol 62(1):37–57
Wang Q, Li Z, Shen J, Keating MT (1996) Genomic organization of the human SCN5A gene encoding the cardiac sodium channel. Genomics 34(1):9–16. https://doi.org/10.1006/geno.1996.0236
Wang Y, Mi J, Lu K, Lu Y, Wang K (2015) Comparison of gating properties and use-dependent block of Nav1.5 and Nav1.7 channels by anti-arrhythmics mexiletine and lidocaine. PLoS ONE 10(6):e0128653
Yu FH, Catterall WA (2003) Overview of the voltage-gated sodium channel family. Genome Biol 4(3):207
Acknowledgements
This study was supported by the Research Fund of the Ministry of Science, ICT and Future Planning (NRF-2020R1A2B5B02001804) and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1A2B4011333, NRF-2018R1A6A1A03025108).
Author information
Authors and Affiliations
Contributions
CJH performed the experiments of electrophysiology. CJH and REK analyzed the data and prepared the figures and tables. YYC and JSC performed the experiment design and the data evaluation. CJH and JSC wrote the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Author CJH declares that he has no conflict of interest. Author REK declares that she has no conflict of interest. Author YYC declares that he has no conflict of interest. Author JSC declares that he has no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Choi, Jh., Kim, RE., Cho, YY. et al. Stable expression of human Nav1.5 for high-throughput cardiac safety assessment. Mol. Cell. Toxicol. 19, 395–402 (2023). https://doi.org/10.1007/s13273-023-00331-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13273-023-00331-8